CD16
| Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | |
|---|---|
| Identifiers | |
| Symbol | FCGR3A |
| Alt. symbols | FCGR3, FCG3 |
| Entrez | 2214 |
| HUGO | 3619 |
| OMIM | 146740 |
| RefSeq | NM_000569 |
| UniProt | P08637 |
| Other data | |
| Locus | Chr. 1 q23 |
| Fc fragment of IgG, low affinity IIIb, receptor (CD16b) | |
|---|---|
| Identifiers | |
| Symbol | FCGR3B |
| Alt. symbols | FCGR3, FCG3 |
| Entrez | 2215 |
| HUGO | 3620 |
| OMIM | 610665 |
| RefSeq | NM_000570 |
| UniProt | O75015 |
| Other data | |
| Locus | Chr. 1 q23 |
CD16 is a low affinity Fc receptor.
It is a cluster of differentiation molecule found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.[1] It can be used to isolate populations of these cells by antibodies directed towards CD16, using fluorescent-activated cell sorting or magnetic-activated cell sorting.
Function
CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies which then activates the NK cell for antibody-dependent cell-mediated cytotoxicity. A lack of CD16 in a given population of neutrophils may indicate prematurity, as could be caused by a left shift due to neutrophilic leukocytosis induced by tissue necrosis or bacterial infection.[2]
As a drug target
Margetuximab targets CD16A in preference to CD16B.[3]
References
- ↑ Janeway, Charles (2001). "Appendix II. CD antigens". Immunobiology (5 ed.). New York: Garland. ISBN 0-8153-3642-X.
- ↑ Vidranski, V; Laskaj, R; Sikiric, D; Skerk, V (2015). "Platelet satellitism in infectious disease?". Biochem Med (Zagreb). 25: 285–94. PMC 4470096
. PMID 26110042. doi:10.11613/BM.2015.030. - ↑ "Margetuximab". AdisInsight. Retrieved 1 February 2017.
External links
- CD16 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH)